US › Healthcare

Pulmonx Corp (LUNG)

US · Healthcare · Medical Devices

$1.98+1.54%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$22.8M

Revenue YoY

-4.6%

Net profit

$-10.1M

EPS

$-0.24

EPS estimate

$-0.28

Net margin

-44.3%

EPS came in at -0.24 against a street estimate of -0.28 — a beat of 14.3%.

Key statistics

Market cap

$82.0M

Forward P/E

28.3

P/B

2.17

Book value

$0.91

EPS (TTM)

$-1.15

52-week high

$2.89

52-week low

$1.13

50-day MA

$1.88

200-day MA

$1.69

Beta

0.34

Analyst view

Analysts rate Pulmonx Corp a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $3.40.

Shareholding

Insiders

4.64%

Institutions

62.80%

Largest institutional holders

Fund	Stake
PRIMECAP Management Company	10.74%
Morgan Stanley - Brokerage Accounts	9.30%
Soleus Capital Management, L.P.	6.49%
BlackRock Inc	6.20%
ExodusPoint Capital Management, LP	4.53%
Vanguard Capital Management, LLC	3.81%
Bank of America Corp	2.72%
Deutsche Bank AG	2.71%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pulmonx Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.